STOML2蛋白在前列腺癌与前列腺增生中的差异表达及意义

发布时间：2018-01-09 08:05

  本文关键词：STOML2蛋白在前列腺癌与前列腺增生中的差异表达及意义　出处：《华北理工大学》2016年硕士论文　论文类型：学位论文

  更多相关文章： STOML2 前列腺癌 免疫组化 蛋白质印迹法 Q-PCR

【摘要】：目的检测STOML2蛋白在前列腺癌和前列腺增生组织中的表达情况,以及初步探讨STOML2蛋白在前列腺癌发生发展过程中的作用。方法采用免疫组织化学方法,对收集的30例前列腺癌和30例前列腺增生患者病理切片进行免疫组化检测,检测STOML2蛋白的表达情况,用费舍尔确切概率法进行统计。对前列腺癌患者临床资料进行整理并分组,检测每组中STOML2蛋白表达情况,并分析它们之间的相关性,用秩和检验进行统计。提取4例前列腺癌和4例前列腺增生术后标本中的蛋白及总RNA,采用蛋白质印迹法及Q-PCR实验方法检测前列腺癌与前列腺增生标本中各自的STOML2蛋白含量及m RNA含量,用独立样本t检验进行统计。结果在30例前列腺癌患者中,STOML2蛋白阳性表达24例,阴性表达6例,阳性表达率为80%(24/30);在30例前列腺增生患者中,STOML2蛋白阳性表达4例,阴性表达26例,阳性表达率为13.3%(4/30),经统计学分析发现在前列腺癌组与前列腺增生组STOML2蛋白表达具有统计学意义(P0.05)。STOML2蛋白在有远处转移组中阳性表达17例,阴性表达1例,阳性表达率为94.4%(17/18);在无远处转移组中阳性表达7例,阴性表达5例,阳性表达率为58.3%(7/12)。经统计分析发现在远处转移分组中STOML2蛋白表达具有统计学意义(P0.05)。在前列腺患者年龄分组、术前PSA分组、前列腺体积分组、Gleason评分分组、临床分期分组、有无淋巴结转移分组中STOML2蛋白表达均无统计学意义(P0.05)。前列腺癌患者术后组织标本中STOML2蛋白含量为(1.67±0.36);前列腺增生患者术后组织标本中STOML2蛋白含量为(0.80±0.19)。经统计学分析前列腺癌组与前列腺增生组中STOML2蛋白含量差异具有统计学意义(P0.05)。前列腺癌患者术后组织标本中STOML2基因m RNA含量为(1.97±0.67);前列腺增生患者术后组织标本中STOML2基因m RNA含量为(0.63±0.32)。经统计学分析前列腺组与前列腺增生组中STOML2基因m RNA含量差异具有统计学意义(P0.05)。结论STOML2在前列腺癌组织中阳性表达率高于前列腺增生组织;STOML2在前列腺癌标本中的蛋白含量及m RNA含量高于前列腺增生组织标本。提示STOML2蛋白在前列腺癌患者中高表达及含量增加,与前列腺癌的发生关系密切。STOML2蛋白表达与前列腺癌患者有无远处转移具有相关性,即STOML2蛋白表达与远处转移呈正相关关系。提示随着前列腺癌患者病情的发展,STOML2蛋白表达量升高,在前列腺发展过程发挥着重要作用。
[Abstract]:Objective to detect the expression of STOML2 protein in prostate cancer and prostatic hyperplasia. To explore the role of STOML2 protein in the development of prostate cancer. Methods Immunohistochemical method was used. The pathological sections of 30 cases of prostate cancer and 30 cases of prostatic hyperplasia were examined by immunohistochemistry to detect the expression of STOML2 protein. The clinical data of patients with prostate cancer were collected and grouped to detect the expression of STOML2 protein in each group and to analyze the correlation between them. The protein and total RNA were extracted from 4 cases of prostate cancer and 4 cases of prostatic hyperplasia by rank sum test. The contents of STOML2 protein and m RNA in prostate cancer and prostatic hyperplasia were detected by Western blot and Q-PCR. Results among 30 patients with prostate cancer, 24 cases had positive expression of STOML2 protein, 6 cases had negative expression, and the positive rate was 80% 24 / 30%. In 30 patients with benign prostatic hyperplasia (BPH), positive expression of STOML2 protein was found in 4 cases and negative expression in 26 cases. The positive rate was 13. 3% / 30). The expression of STOML2 protein in prostate cancer group and prostatic hyperplasia group was statistically significant. 17 cases with distant metastasis showed positive expression of STOML2 protein. Negative expression was found in 1 case, the positive expression rate was 94. 4% or 17 / 18; In the group without distant metastasis, 7 cases were positive and 5 cases were negative. The positive expression rate was 58.3% / 12%. Statistical analysis showed that the expression of STOML2 protein in distant metastasis group was statistically significant (P 0.05). Preoperative PSA group, prostate volume group, Gleason score group, clinical staging group. There was no significant difference in the expression of STOML2 protein in lymph node metastasis group. The content of STOML2 protein was 1.67 卤0.36 in postoperative tissue samples of patients with prostate cancer. ; The content of STOML2 protein was 0.80 卤0.19 in the tissue of patients with prostatic hyperplasia after operation. The difference of STOML2 protein content between prostate cancer group and prostatic hyperplasia group was statistically significant (P 0.05). The content of m RNA of STOML2 gene was 1.97 卤0.67 in the tissue of patients with prostate cancer after operation. The content of STOML2 gene m RNA was 0.63 卤0.32 in postoperative tissue samples of patients with benign prostatic hyperplasia (BPH). The difference of m RNA content of STOML2 gene between prostatic group and prostatic hyperplasia group was statistically significant (P0.05). Conclusion the positive expression rate of STOML2 in prostate cancer is higher than that in prostatic hyperplasia. The protein content and m RNA content of STOML2 in prostate cancer samples were higher than those in benign prostatic hyperplasia tissues, suggesting that the expression and content of STOML2 protein were increased in prostate cancer patients. The expression of STOML2 protein is closely related to the occurrence of prostate cancer. There is a correlation between the expression of STOML2 protein and the distant metastasis of prostate cancer patients. That is, the expression of STOML2 protein is positively correlated with distant metastasis, which suggests that the expression of STOML2 protein increases with the development of prostate cancer, and plays an important role in the development of prostate cancer.
【学位授予单位】：华北理工大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R737.25;R697.3
，

本文编号：1400604